Kraj M, Rostkowska J, Sokołowska U, Maj S
Kliniki Hematologicznej Instytutu Hematologii, Warszawie.
Acta Haematol Pol. 1991;22(1):42-7.
Out of 436 studied patients with plasmocytic myeloma 67 (15.0%) survived over 5 years from the beginning of antineoplastic treatment, and 18 survived over 10 years from the first symptom of the proliferative process. The patients with long survival were younger at the time of diagnosis than the whole studied group and had normal creatinine and calcium levels in the serum. Nearly half these patients had I or II stage of clinical progression and IgG monoclonal protein. Treatment with melphalan only was given to 17 patients, 33 were treated with melphalan, followed by vincristine, cyclophosphamide, BCNU, prednisone and doxorubicin. Polychemotherapy was given from the time of the diagnosis to 13 patients, and 4 received radiotherapy or 60Co irradiation besides chemotherapy. In 81% of the analysed cases a good response was obtained. Thirteen patients are alive. In 5 cases myeloid leukaemia, in 1 case bronchogenic carcinoma and in 1 case liver carcinoma were the causes of death.
在436例接受研究的浆细胞骨髓瘤患者中，67例（15.0%）自抗肿瘤治疗开始后存活超过5年，18例自增殖性疾病的首发症状起存活超过10年。长期存活的患者在诊断时比整个研究组患者年轻，且血清肌酐和钙水平正常。这些患者中近一半处于临床进展I期或II期，并有IgG单克隆蛋白。仅用美法仑治疗的患者有17例，33例接受美法仑治疗，随后接受长春新碱、环磷酰胺、卡莫司汀、泼尼松和多柔比星治疗。13例患者自诊断时起接受多药化疗，4例除化疗外还接受了放疗或60钴照射。在81%的分析病例中获得了良好反应。13例患者仍存活。5例死于髓细胞白血病，1例死于支气管源性癌，1例死于肝癌。
